DORFSTRASSE 29, ZUG, V8
MoonLake Reports Positive Results from Phase 3 Sonelokimab Trial and Q2 2026 Financials
Other Events
MoonLake Immunotherapeutics Enters Underwriting Agreement for 9M Shares
Investor Day June 22nd, 2026
MoonLake Immunotherapeutics Increases Equity Incentive Plan Shares by 5 Million
Master Commercial Supply Agreement with Vetter Pharma International
Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence